A Randomized Phase II Study of Tiragolumab plus Atezolizumab and Standard Chemotherapy versus Placebo plus Pembrolizumab and Standard Chemotherapy in People with Advanced Non-Squamous Non-Small Cell Lung Cancer


Full Title

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer


Researchers are doing this study to find out whether tiragolumab, atezolizumab, and standard chemotherapy may be a safe and effective treatment in people with previously untreated inoperable or metastatic non-squamous non-small cell lung cancer (NSCLC), and to see whether this therapy may be better than treatment with a placebo plus pembrolizumab immunotherapy and standard chemotherapy.

Tiragolumab, atezolizumab, and pembrolizumab are all immunotherapies; they take the brakes off the immune system, enabling immune cells to find and kill cancer cells. Patients in this study will be randomly assigned to receive either tiragolumab, atezolizumab, and chemotherapy OR pembrolizumab, chemotherapy, and a placebo. The treatments in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic NSCLC.
  • Patients may not have received prior treatment for advanced cancer.
  • Patients whose tumors contain a mutation in the EGFR gene or an ALK fusion oncogene may not participate in this study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew Hellmann at 646-608-3762.